Mechanisms involved in follistatin‐induced hypertrophy and increased insulin action in skeletal muscle
Open accessPublished version of a preprint
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background: Skeletal muscle wasting is often associated with insulin resistance. A major regulator of muscle mass is the transforming growth factor β (TGF‐β) superfamily, including activin A, which causes atrophy. TGF‐β superfamily ligands also negatively regulate insulin‐sensitive proteins, but whether this pathway contributes to insulin action remains to be determined. Methods: To elucidate if TGF‐β superfamily ligands regulate insulin action, we used an adeno‐associated virus gene editing approach to overexpress an activin A inhibitor, follistatin (Fst288), in mouse muscle of lean and diet‐induced obese mice. We determined basal and insulin‐stimulated 2‐deoxy‐glucose uptake using isotopic tracers in vivo . Furthermore, to evaluate whether circulating Fst and activin A concentrations are associated with obesity, insulin resistance, and weight loss in humans, we analysed serum from morbidly obese subjects before, 1 week, and 1 year after Roux‐en‐Y gastric bypass (RYGB). Results: Fst288 muscle overexpression markedly increased in vivo insulin‐stimulated (but not basal) glucose uptake (+75%, P < 0.05) and increased protein expression and intracellular insulin signalling of AKT, TBC1D4, PAK1, pyruvate dehydrogenase‐E1α, and p70S6K, while decreasing TBC1D1 signaling ( P < 0.05). Fst288 increased both basal and insulin‐stimulated protein synthesis, but no correlation was observed between the Fst288‐driven hypertrophy and the increase in insulin‐stimulated glucose uptake. Importantly, Fst288 completely normalized muscle glucose uptake in insulin‐resistant diet‐induced obese mice. RYGB surgery doubled circulating Fst and reduced activin A (−24%, P < 0.05) concentration 1 week after surgery before any significant weight loss in morbidly obese normoglycemic patients, while major weight loss after 1 year did not further change the concentrations. Conclusions: We here present evidence that Fst is a potent regulator of insulin action in muscle, and in addition to AKT and p70S6K, we identify TBC1D1, TBC1D4, pyruvate dehydrogenase‐E1α, and PAK1 as Fst targets. Circulating Fst more than doubled post‐RYGB surgery, a treatment that markedly improved insulin sensitivity, suggesting a role for Fst in regulating glycaemic control. These findings demonstrate the therapeutic potential of inhibiting TGF‐β superfamily ligands to improve insulin action and Fst's relevance to muscle wasting‐associated insulin‐resistant conditions in mice and humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
SUnSET, a nonradioactive method to monitor protein synthesis
Schmidt, E. K., Clavarino, G., Ceppi, M., & Pierre, P. (2009) · Nature Methods · doi:10.1038/nmeth.1314 · Cited by 1,706
Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583
DeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167 · cited 3×
“Furthermore, skeletal muscle plays a critical role in glycemic control as it accounts up to 75% of insulin-stimulated glucose disposal in humans [2].”
BackgroundCusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., & Mandarino, L. J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7535 · Cited by 1,139 · cited 2×
“Several common conditions are associated with muscle wasting and/or insulin resistance, including cancer cachexia [3], [4], sarcopenia [5], [6], and type 2 diabetes [2], [7], [8].”
BackgroundSuppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505
Exercise-stimulated glucose uptake — regulation and implications for glycaemic control
Sylow, L., Kleinert, M., Richter, E. A., & Jensen, T. E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.162 · Cited by 498 · cited 1×
“delivery, transport across the muscle cell surface by the glucose transporter GLUT4 and intramyocellular metabolism.(68) In the present study, GLUT4 expression was unchanged with Fst288, while the intracellular signals to translocate GLUT4 to the plasma membrane were greatly enhanced.”
BackgroundSelf-citationKim, Y.-B., Nikoulina, S. E., Ciaraldi, T. P., Henry, R. R., & Kahn, B. B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6928 · Cited by 487
Coomassie staining as loading control in Western blot analysis
Welinder, C., & Ekblad, L. (2011) · Journal of Proteome Research · doi:10.1021/pr1011476 · Cited by 463 · cited 1×
“Coomassie brilliant blue staining was used as a loading control.(32) Bands were visualized using the Bio-Rad ChemiDoc MP Imaging System and enhanced chemiluminescence (ECL+; Amersham Biosciences).”
MethodTurner, N., Kowalski, G. M., Leslie, S. J., Risis, S., Yang, C., Lee-Young, R. S., Babb, J. R., Meikle, P. J., Lancaster, G. I., Henstridge, D. C., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2913-1 · Cited by 430 · cited 1×
“Importantly, at this time of the HFD intervention, muscular insulin resistance has already set in [33], [34], thus allowing us to test the therapeutic potential for Fst in restoring insulin sensitivity in already insulin resistant muscle.”
BackgroundGuo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004937 · Cited by 402 · cited 3×
“So, in addition to the effects of Fst on key insulin sensitive proteins and glucose incorporation into glycogen, Fst also increased PDH activity in gastrocnemius muscle, suggesting greater capacity for glycolysis-driven mitochondrial glucose oxidation.(52) This is in line with a previ-”
BackgroundInfluentialFollistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis
Amthor, H., Nicholas, G., McKinnell, I., Kemp, C. F., Sharma, M., Kambadur, R., & Patel, K. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.01.046 · Cited by 401
Gilson, H., Schakman, O., Kalista, S., Lause, P., Tsuchida, K., & Thissen, J.-P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00193.2009 · Cited by 248
Rooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244
Winbanks, C. E., Weeks, K. L., Thomson, R. E., Sepulveda, P. V., Beyer, C., Qian, H., Chen, J. L., Allen, J. M., Lancaster, G. I., Febbraio, M. A., et al. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201109091 · Cited by 218 · cited 3×
“The purified vector preparations were titred with a customized sequence-specific quantitative PCR-based reaction (Applied Biosystems).(12)”
MethodResultInfluentialSelf-citationActivin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185 · cited 1×
“A major regulator of muscle mass is the transforming growth factor β (TGF-β) superfamily, including activin A and myostatin, among which activin A is most relevant to humans.(9) Activin A”
BackgroundPehmøller, C., Treebak, J. T., Birk, J. B., Chen, S., MacKintosh, C., Hardie, D. G., Richter, E. A., & Wojtaszewski, J. F. P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00115.2009 · Cited by 171
Self-citationThe effects of a soluble activin type IIB receptor on obesity and insulin sensitivity
Akpan, I., Goncalves, M. D., Dhir, R., Yin, X., Pistilli, E. E., Bogdanovich, S., Khurana, T. S., Ucran, J., Lachey, J., & Ahima, R. S. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.162 · Cited by 140 · cited 1×
“For example, pharmacological inhibition or genetic deletion of the Fst targets, myostatin or activin A, protects against HFD-induced obesity [40]–[42].”
BackgroundCirculating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio
Hansen, J. S., Rutti, S., Arous, C., Clemmesen, J. O., Secher, N. H., Drescher, A., Gonelle-Gispert, C., Halban, P. A., Pedersen, B. K., Weigert, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3668 · Cited by 125
Potential role of TBC1D4 in enhanced post-exercise insulin action in human skeletal muscle
Treebak, J. T., Frøsig, C., Pehmøller, C., Chen, S., Maarbjerg, S. J., Brandt, N., MacKintosh, C., Zierath, J. R., Hardie, D. G., Kiens, B., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1294-y · Cited by 119 · cited 2×
“Given that our findings show TBC1D4 phosphorylation as a target for Fst, it would be relevant for future studies to elucidate a potential role for Fst in post-exercise-enhanced glucose uptake, which also impinges on TBC1D4.(74,75)”
BackgroundSelf-citationTreebak, J. T., Pehmøller, C., Kristensen, J. M., Kjøbsted, R., Birk, J. B., Schjerling, P., Richter, E. A., Goodyear, L. J., & Wojtaszewski, J. F. P. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2013.266338 · Cited by 113
Self-citationInactivating hepatic follistatin alleviates hyperglycemia
Tao, R., Wang, C., Stöhr, O., Qiu, W., Hu, Y., Miao, J., Dong, X. C., Leng, S., Stefater, M., Stylopoulos, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0048-0 · Cited by 104
Contraction regulates site-specific phosphorylation of TBC1D1 in skeletal muscle
Vichaiwong, K., Purohit, S., An, D., Toyoda, T., Jessen, N., Hirshman, M. F., & Goodyear, L. J. (2010) · Biochemical Journal · doi:10.1042/bj20101100 · Cited by 102
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
A complex role of activin A in non-alcoholic fatty liver disease
Yndestad, A., Haukeland, J. W., Dahl, T. B., Bjøro, K., Gladhaug, I. P., Berge, C., Damås, J. K., Haaland, T., Løberg, E. M., Linnestad, P., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.318 · Cited by 75 · cited 1×
“However, contrasting with Fst’s proposed beneficial role in insulin sensitivity, plasma Fst is actually slightly elevated in patients with type 2 diabetes(59) and in non-alcoholic fatty liver disease.(60) Those studies did not analyse activin A.”
BackgroundHansen, J., Rinnov, A., Krogh‐Madsen, R., Fischer, C. P., Andreasen, A. S., Berg, R. M. G., Møller, K., Pedersen, B. K., & Plomgaard, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2415 · Cited by 71 · cited 2×
“[47] J.”
Davey, J. R., Watt, K. I., Parker, B. L., Chaudhuri, R., Ryall, J. G., Cunningham, L., Qian, H., Sartorelli, V., Sandri, M., Chamberlain, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85477 · Cited by 51
Self-citation
Research works printed but not linked: 50
- 10.1016/S0140-6736(14)62000-6 · DOI · Paper page
- 10.1093/annonc/mdx815 · DOI · Paper page
- 10.1038/521430a · DOI
- 10.1530/JOE-15-0533 · DOI · Paper page
- 10.1096/fj.05-4607fje · DOI · Paper page
- 10.2337/db07-0887 · DOI · Paper page
- 10.1096/fj.07-8673com · DOI · Paper page
- 10.1126/scitranslmed.3000112 · DOI · Paper page
- 10.1124/jpet.113.211169 · DOI
- 10.1038/srep17535 · DOI
- 10.1016/j.ymthe.2017.02.015 · DOI · Paper page
- 10.1016/j.cellsig.2013.11.007 · DOI
- 10.2337/db06-0823 · DOI · Paper page
- 10.2337/db12-1148 · DOI · Paper page
- 10.1016/j.ymthe.2004.07.016 · DOI · Paper page
- 10.1042/bj2280103 · DOI · Paper page
- 10.1074/jbc.M408312200 · DOI · Paper page
- 10.1113/JP275602 · DOI · Paper page
- 10.1016/0003-2697(67)90167-4 · DOI · Paper page
- 10.2337/db13-1307 · DOI · Paper page
- 10.2337/db06-0152 · DOI · Paper page
- 10.1152/ajpregu.00400.2010 · DOI
- 10.1126/science.1106148 · DOI · Paper page
- 10.1007/s00125-014-3395-5 · DOI · Paper page
- 10.1042/BJ20071114 · DOI · Paper page
- 10.1021/acs.jproteome.7b00069 · DOI
- 10.1113/jphysiol.2004.076158 · DOI · Paper page
- 10.1152/ajpendo.00526.2002 · DOI · Paper page
- RocheTE BakerJC YanX HiromasaY GongX PengTet al.Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms.2001. pp.33–75. · DOI · Paper page
- 10.1038/emm.2001.32 · DOI · Paper page
- 10.1038/nrendo.2017.161 · DOI · Paper page
- 10.2337/diabetes.53.suppl_3.S215 · DOI · Paper page
- 10.1111/j.1464-5491.1992.tb01813.x · DOI · Paper page
- 10.1007/s00335-014-9533-z · DOI · Paper page
- 10.1152/ajpregu.00228.2014 · DOI · Paper page
- 10.2147/DMSO.S159315 · DOI
- 10.1016/S1357-2725(98)00064-8 · DOI
- 10.1530/REP-07-0208 · DOI
- 10.1210/jc.2011-1665 · DOI · Paper page
- 10.1074/jbc.270.50.29928 · DOI · Paper page
- 10.1210/en.2011-1687 · DOI
- 10.1093/ajcn/82.2.355 · doi:10.1093/ajcn/82.2.355
- 10.1016/j.cmet.2013.03.015 · DOI · Paper page
- 10.1042/BST20170479 · DOI · Paper page
- 10.1210/en.2012-2147 · DOI · Paper page
- 10.1002/jbmr.2285 · DOI · Paper page
- 10.1016/j.bbrc.2013.10.005 · DOI
- 10.2337/db11-1572 · DOI · Paper page
- 10.1038/mt.2014.200 · DOI · Paper page
- 10.1002/jcsm.12261 · DOI · Paper page
Cited by
The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia
Sylow, L., Tokarz, V. L., Richter, E. A., & Klip, A. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.020 · Cited by 366
Self-citationEgan, B., & Sharples, A. P. (2023) · Physiological Reviews · doi:10.1152/physrev.00054.2021 · Cited by 278
Roberts, M. D., McCarthy, J. J., Hornberger, T. A., Phillips, S. M., Mackey, A. L., Nader, G. A., Boppart, M. D., Kavazis, A. N., Reidy, P. T., Ogasawara, R., et al. (2023) · Physiological Reviews · doi:10.1152/physrev.00039.2022 · Cited by 214
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Seo, M.-W., Jung, S.-W., Kim, S.-W., Lee, J.-M., Jung, H. C., & Song, J.-K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136762 · Cited by 130
“In contrast, follistatin has a decisive role in myostatin-inhibiting activity and muscle hypertrophy [15].”
Background
Metadata
- Authors
- Han, X., Møller, L. L. V., De Groote, E., Bojsen‐Møller, K. N., Davey, J., Henríquez‐Olguin, C., Li, Z., Knudsen, J. R., Jensen, T. E., Madsbad, S., Gregorevic, P., Richter, E. A., & Sylow, L.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2019-08-11
- Volume
- 10
- Issue
- 6
- Pages
- 1241-1257
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2967247987
- Cited by
- 75
- References
- 27
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Comisión Nacional de Investigación Científica y Tecnológica
- China Scholarship Council
- Novo Nordisk Fonden (#32082, #15182)
- Natur og Univers, Det Frie Forskningsråd (DFF‐6108‐00203A, DFF‐4004‐00233)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.